Isolation of fusion-competent myoblasts and therapeutic applications thereof related to muscular dystrophy
Described are methods of isolating high purity myoblasts that are used to create novel DMD model systems and methods using human induced pluripotent stem cells (hiPSCs). Also described are therapeutic methods based on the use of these myoblasts..
| Medienart: |
|
|---|
Patent| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Europäisches Patentamt - (2022) vom: 03. Mai Zur Gesamtaufnahme - year:2022 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
LEE GABSANG [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Anmerkungen: |
Source: www.epo.org (no modifications made), First posted: 2022-05-03, Last update posted on www.tib.eu: 2023-12-21, Last updated: 2023-12-29 |
|---|
| Patentnummer: |
US11318167 |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
EPA013346776 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | EPA013346776 | ||
| 003 | DE-627 | ||
| 005 | 20231229105105.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230215s2022 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)EPA013346776 | ||
| 035 | |a (EPA)US11318167 | ||
| 035 | |a (EPA)59013559 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 0 | |a LEE GABSANG |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Isolation of fusion-competent myoblasts and therapeutic applications thereof related to muscular dystrophy |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Source: www.epo.org (no modifications made), First posted: 2022-05-03, Last update posted on www.tib.eu: 2023-12-21, Last updated: 2023-12-29 | ||
| 520 | |a Described are methods of isolating high purity myoblasts that are used to create novel DMD model systems and methods using human induced pluripotent stem cells (hiPSCs). Also described are therapeutic methods based on the use of these myoblasts. | ||
| 650 | 4 | |a bio | |
| 650 | 4 | |a tec | |
| 650 | 4 | |a A61K: Preparations for medical, dental, or toilet purposes (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms a61j0003000000;chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles a61l; soap compositions c11d) | |
| 650 | 4 | |a G01N: Investigating or analysing materials by determining their chemical or physical properties (measuring or testing processes other than immunoassay, involving enzymes or microorganisms c12m, c12q) | |
| 650 | 4 | |a A61P: Specific therapeutic activity of chemical compounds or medicinal preparations | |
| 650 | 4 | |a C12N: Microorganisms or enzymes; compositions thereof; propagating, preserving, or maintaining microorganisms; mutation or genetic engineering; culture media (microbiological testing media c12q0001000000) | |
| 650 | 4 | |a che | |
| 650 | 4 | |a 615 | |
| 700 | 0 | |a CHOI INYOUNG |4 aut | |
| 700 | 0 | |a LIM HOTAE |4 aut | |
| 700 | 0 | |a WAGNER KATHRYN R |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Europäisches Patentamt |g (2022) vom: 03. Mai |
| 773 | 1 | 8 | |g year:2022 |g day:03 |g month:05 |
| 856 | 4 | 0 | |u https://worldwide.espacenet.com/patent/search/family/59013559/publication/US11318167A1?q=US11318167 |z kostenfrei |3 Volltext |
| 912 | |a GBV_EPA | ||
| 936 | u | w | |j 2022 |b 03 |c 05 |
| 951 | |a AR | ||
| 952 | |j 2022 |b 03 |c 05 | ||